BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
BIOMERICA INC
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026
$1.76−0.09 (-4.86%)
Close on Oct 19, 2026
- Market cap
- $5.80M
- P/E (TTM)
- –
- Dividend yield
- –
BIOMERICA INC revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Lab [Member] | – | – | – | – | $3.06M | $3.08M | $2.92M | $4.04M | – | – | – | – |
| OTC [Member] | – | – | – | – | – | – | $1.27M | $868.61K | – | – | – | – |
| Physician's office [Member] | – | – | – | – | $14.26M | $2.80M | $2.20M | $170.87K | – | – | – | – |
| Contract Manufacturing [Member] | – | – | – | – | $459.00K | $555.00K | $306.00K | $117.21K | – | – | – | – |
| Over-the-counter [Member] | – | – | – | – | $1.09M | $766.00K | $1.27M | – | – | – | – | – |
| Lab Supplies [Member] | – | – | – | – | – | $3.00K | – | – | – | – | – | – |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical Lab [Member] | $2.73M | $3.18M | $3.24M | $3.31M | $3.06M | – | – | – | – | – | 61.4% | -14.1% |
| Contract Manufacturing [Member] | $891.00K | $1.07M | $741.00K | $610.00K | $459.00K | – | – | – | – | – | 20.0% | -16.7% |
| Over-The-Counter [Member] | $821.00K | $1.05M | $1.43M | $1.17M | $1.09M | – | – | – | – | – | 18.4% | -21.7% |
| Physician's office [Member] | $9.00K | $11.00K | $12.00K | $250.00K | $14.26M | – | – | – | – | – | 0.2% | -18.2% |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North America [Member] | $1.47M | $1.66M | $1.29M | $1.47M | $997.00K | $548.00K | – | – | – | – | 32.9% | -11.6% |
| Asia [Member] | $1.41M | $1.72M | $1.88M | $2.02M | $13.38M | $1.91M | $1.87M | $2.51M | $2.51M | $2.41M | 31.6% | -18.0% |
| Europe [Member] | $1.12M | $1.30M | $1.44M | $1.80M | $4.34M | $4.30M | $2.43M | $1.69M | $2.02M | $2.24M | 25.1% | -13.9% |
| Middle East [Member] | $446.00K | $630.00K | $800.00K | $39.00K | $70.00K | $192.00K | $314.00K | $214.00K | $132.00K | $186.00K | 10.0% | -29.2% |
| South America [Member] | $15.00K | $8.00K | $11.00K | $11.00K | $90.00K | $250.00K | $1.62M | $256.00K | $214.00K | $65.00K | 0.3% | +87.5% |
| Other Foreign [Member] | – | – | – | – | – | – | $18.00K | – | $4.00K | $17.00K | – | – |
| United States | – | – | – | – | – | $548.00K | $445.00K | $523.00K | $685.00K | $874.00K | – | – |
| Other [Member] | – | – | – | – | – | – | $18.00K | – | – | – | – | – |
From the segment and revenue-disaggregation notes of Biomerica's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.